Nasdaq

A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its participation in almost ...
TMCnet

Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm

Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to platinum-based chemotherapy or PARP inhibitors. Unlike traditional DNA tests ...
Business Wire

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a ...
Business Wire

Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its ...
Nasdaq

Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer

Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines. “Staying current with rapidly evolving clinical guidelines—especially regarding biomarker ...